Reducing Adult Smoking: FDA Needs to Lead the Charge

Nov.28.2022
Reducing Adult Smoking: FDA Needs to Lead the Charge
US teen e-cigarette use declines, however, adult smoking still needs to see progress in reducing numbers.

Author Background: Dr. Matthew Holman is the Vice President in charge of regulatory strategy for PMI in the United States. Prior to joining Philip Morris in September, Holman served as the Director of the Office of Science at the FDA's Center for Tobacco Products.


Source: Duluth News Tribune, image provided by Matthew Holman.


The latest data from the National Youth Tobacco Survey tells a story that you may not have heard before. The U.S. Food and Drug Administration and Centers for Disease Control and Prevention recently released the results of the 2022 survey, which showed a decrease in underage e-cigarette use to levels below the "epidemic" announced by the FDA in 2018. The data shows a continued reversal of the trend.


According to the same data, the percentage of teenagers smoking combustible cigarettes is at its lowest historical level of 1.6%. In fact, over the past few years, there has been a significant decrease in the use of all tobacco products among adolescents. Many stakeholders, including myself, have tirelessly worked towards reducing underage usage and have achieved success.


However, according to data from the American Cancer Society, the decrease in the number of adult smokers has not matched this progress, with 34 million smokers currently in the United States.


The FDA could do more to help Americans quit smoking and should engage in conversations with smokers again, just like it did before releasing the 2018 Tobacco Survey results.


Smoking among adults has also decreased, although not significantly, much like among teenagers. According to public health data, smoking remains the largest single preventable cause of death in the United States. Therefore, while acknowledging the significant progress made in recent years in reducing tobacco use among youths is important, it is equally important to recognize that too many Americans still smoke.


As a senior professional at the FDA for 20 years and recently appointed as the top scientist for the agency's Center for Tobacco Products, I am aware that it is home to talented scientists who want to do more to help smokers make better choices than continuing to smoke - while also preventing underage nicotine use.


So, what can be done to speed up the reduction of adult smoking in the United States? The US public health agencies need to adopt a more balanced approach in promoting tobacco and nicotine products, which is an urgently needed and important strategic move.


The FDA has invested a significant amount of funds in launching multiple multimedia campaigns aimed at reducing underage electronic cigarette use among adolescents and parents. These efforts should continue. However, what is completely missing is similar investment in communicating with adult smokers. The FDA must engage smokers in a consistent, transparent, and meaningful way to help them quit smoking altogether or encourage those who don't quit to switch to innovative smoke-free products. The FDA acknowledges that such products are a better alternative to continuing smoking. Let's make sure adult smokers know this.


The message that all Americans need to hear from health experts is simple: if you don't currently use tobacco products, don't start. If you smoke, quitting is the best option. If you don't quit, switch to smoke-free alternatives. This message is scientifically supported, and the FDA's authorization of nicotine products confirms this. For adult smokers who completely switch to nicotine products, the chance of exposure to harmful chemicals in smoke is significantly reduced, and for certain products, the risk of lung cancer and other smoking-related diseases may be decreased.


Today, smokers are not receiving this crucial message, and that needs to change. Otherwise, nearly 500,000 Americans will continue to die unnecessarily every year. Health experts have a responsibility to proactively share information about better choices with adult smokers, while also continuing to prevent underage tobacco use.


When I was working at the FDA, Commissioner Scott Gottlieb announced a comprehensive plan aimed at getting smokers to switch from traditional combustible cigarettes to less harmful tobacco products or to quit tobacco altogether. The plan was unveiled over five years ago, but until now, the FDA's efforts have primarily focused on preventing underage use. It is now time to take action to assist adult smokers in making better choices.


I hope that my former colleagues at the FDA, who are all exceptional public health scientists, will take necessary action to accelerate the transition towards a healthier America by keeping smokers away from cigarettes.


Statement:


This article is sourced from compiled third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the accuracy of the content. The translation of this article is solely intended for industry communication and research.


Due to limitations in the translator's skills, the translated article may not accurately reflect the original text. Please consider the original text as the primary source.


2FIRSTS is fully aligned with the position and stance of the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
Denver’s Flavored Tobacco Ban Faces Constitutional Challenge From Vape Trade Group
Denver’s Flavored Tobacco Ban Faces Constitutional Challenge From Vape Trade Group
A Colorado vape industry trade group says Denver’s voter-approved flavored tobacco sales ban is unconstitutional and too vague to enforce. The group is asking a state court for a permanent injunction blocking enforcement of Ordinance 24-1765 and for a declaration allowing flavored tobacco and vape sales, citing state constitutional vagueness concerns and multiple U.S. constitutional issues.
Jan.27 by 2FIRSTS.ai
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Health Canada’s vaping compliance and enforcement report covering inspections from April 2024 to March 2025 found 43% of 546 specialty vaping businesses were not compliant with the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act, according to the report cited. Health inspectors seized vaping products at 235 specialty vaping establishments.
Feb.26 by 2FIRSTS.ai
PMI launches IQOS Iluma i One in the UK, compatible with TEREA tobacco sticks
PMI launches IQOS Iluma i One in the UK, compatible with TEREA tobacco sticks
Philip Morris Limited (PML), the UK affiliate of Philip Morris International (PMI), has launched the latest addition to its heated tobacco IQOS lineup, the IQOS Iluma i One, in the UK. The device uses a bladeless induction-heating system and adds features such as a touchscreen and automatic start-up, while being designed for use with TEREA tobacco sticks, including the Pearls range.
Feb.10 by 2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai